-
DUPIXENT is now recommended for specific use in England and Wales1
-
Use the map to view DUPIXENT reimbursement for the specific regions.
NICE Technology Appraisal Guidance (TA751)1
DUPIXENT is recommended by National Institute for Health and Care Excellence (NICE), as an add-on maintenance therapy option for treating severe asthma with Type 2 inflammation that is inadequately controlled in people 12 years and over, despite maintenance therapy with high-dose inhaled corticosteroids and another maintenance treatment, only if the below criteria are met1
The person has agreed to and followed the optimised standard treatment plan
The dosage used is 400 mg initially and then 200 mg subcutaneously every other week
Blood eosinophils (EOS) ≥150 cells/μL and fraction of exhaled nitric oxide (FeNO) ≥25 ppb
The person has had ≥4 exacerbations in the preceding year
The person is not eligible for biologicals or has asthma that has not responded adequately to biological therapy
The company provides DUPIXENT with the discount agreed in the patient access scheme (PAS)Stop dupilumab if the rate of severe asthma exacerbations has not been reduced by at least a 50% after 12 months.
-
DUPIXENT is reimbursed through the Medicines for Children (M4C) policy.
DUPIXENT qualifies for M4C reimbursement as a medication approved in
adults by a NICE TA and one that has a license for use in children and both
the indication for use and the age of the child fall within those specified in the adult license.2M4C additional criteria2
The patient meets all the NICE TA/NHS England clinical commissioning policy criteria for the proposed medicine/indication
The patient does not meet any exclusion criteria for the medicine indication in question
The use of the drug has been discussed at a multidisciplinary team (MDT) meeting which must include at least two consultants in the subspecialty with active and credible expertise in the relevant field of whom at least one must be a consultant paediatrician. The MDT should include a paediatric pharmacist and other professional groups appropriate to the disease area
The patient has been registered via the NHS England prior approval web-based systemMAT-XU-2204211 (v2.0)
-
DUPIXENT has specific guidance for use in Scotland2
In Scotland, DUPIXENT is accepted for restricted use for severe asthma in patients 12 years and older with blood eosinophils (EOS) ≥150 cells/mL and fraction of exhaled nitric oxide (FeNO) ≥25 ppb, and ≥4 exacerbations in the preceding year, who have previously received biologic treatment with anti-IgE or anti-IL-5 therapies2
Use the map to view DUPIXENT reimbursement for the specific regions.
Scottish Medicines Consortium (SMC) advice2
SMC have restricted the use of DUPIXENT to patients with blood EOS ≥150 cells/μL and FeNO ≥25 ppb, and ≥4 exacerbations in the preceding year, who have previously received biologic treatment with anti-IgE or anti-IL-5 therapies
SMC reviewed DUPIXENT under the context of its indication: as add-on maintenance treatment for severe asthma in adults and adolescents 12 years and older with Type 2 inflammation characterised by raised blood EOS and/or raised FeNO, who are inadequately controlled with high dose inhaled corticosteroids (ICS) plus another medicinal product for maintenance treatment
The SMC advice applies to an approved Patient Access Scheme (PAS) that delivers the cost-effectiveness of DUPIXENT or a PAS/list price that is equivalent or lower
DUPIXENT efficacy
Want to know how DUPIXENT can help your patients? Find out more about the Phase 3 clinical trials of DUPIXENT.
- NICE guidance. Available at: https://www.nice.org.uk/guidance/gid-ta10276/documents/final-appraisal-determination-document. Date last accessed: June 2023.
- NHS England. Commissioning Medicines for Children in Specialised Services. 2017. Available at: https://www.england.nhs.uk/wp-content/uploads/2017/03/
commissioning-medicines-children-specialised-services.pdf. Date last accessed: June 2023. - Scottish Medicines Consortium. Dupilumab (Dupixent). Available at: https://www.scottishmedicines.org.uk/medicines-advice/dupilumab-dupixent-full-smc2317/. Date last accessed: June 2023.
EOS, eosinophils; FeNO, fraction of exhaled nitric oxide; ICS, inhaled corticosteroids; IgE, immunoglobulin E; IL, interleukin; M4C, Medicines for Children; MDT, multidisciplinary team; NHS, National Health Service; NICE, National Institute for Health and Care Excellence;NICE TA, National Institute for Health and Care Excellence Technology PAS, Patient Access Scheme; ppb, parts per billion; SMC, Scottish Medicines Consortium.
References
MAT-GB-2100503 (v10.0) | Date of preparation: June 2023